viral
infect
lead
caus
upper
lower
airway
acut
ill
age
group
otherwis
healthi
individu
also
implic
acut
exacerb
chronic
respiratori
disord
asthma
chronic
obstruct
pulmonari
diseas
copd
human
rhinoviru
hrv
respiratori
syncyti
viru
rsv
influenza
viru
coronavirus
consid
import
viral
respiratori
pathogen
although
parainfluenza
virus
hpiv
common
respiratori
pathogen
caus
infect
without
ethnic
socioeconom
gender
age
geograph
boundari
frequent
induc
acut
respiratori
tract
diseas
infant
immunocompromis
adult
role
exacerb
chronic
respiratori
disord
receiv
rel
littl
attent
nonimmun
compromis
individu
hpiv
infect
typic
transient
mild
howev
patient
asthma
copd
infect
may
associ
sever
respiratori
symptom
exacerb
mind
increas
number
report
potenti
role
parainfluenza
virus
exacerb
chronic
airway
disord
aim
updat
potenti
reader
epidemiolog
immunolog
novel
clinic
aspect
hpiv
infect
asthma
copd
respiratori
syncyti
viru
hpiv
second
common
caus
acut
respiratori
tract
infect
among
children
age
year
possibl
account
hospit
although
agespecif
rate
lower
respiratori
tract
infect
vari
significantli
differ
popul
medic
burden
hpiv
similar
rsv
infect
children
serolog
survey
indic
children
infect
year
age
number
increas
year
age
among
adult
infect
manifest
mild
upper
respiratori
tract
symptom
howev
sever
diseas
may
also
occur
particularli
older
adult
immunocompromis
although
hpiv
infect
occur
throughout
year
sever
studi
document
distinct
tempor
trend
hpiv
serotyp
strong
relationship
observ
hpiv
serotyp
specif
clinic
syndrom
age
child
time
year
infect
occur
peak
season
activ
occur
biennial
late
septemb
decemb
oddnumb
year
season
occur
octob
decemb
peak
season
occur
annual
spring
april
june
may
septemb
england
frost
et
al
recent
describ
yearround
preval
infect
peak
autumn
oddnumb
year
season
activ
also
vari
differ
year
higher
activ
year
circul
convers
significantli
lower
activ
year
peak
activ
phenomena
potenti
reflect
heterotyp
cross
protect
antibodi
human
parainfluenza
virus
belong
divers
group
envelop
singlestrand
rna
virus
within
paramyxovirida
famili
larg
expand
group
virus
includ
metapneumoviru
mump
measl
respiratori
syncyti
virus
base
genet
antigen
analys
hpiv
divid
four
major
subtyp
classifi
respiroviru
rubulaviru
genera
within
paramyxovirina
subfamili
tabl
hpiv
may
phenotyp
distinguish
member
paramyxovirida
base
neuraminidas
express
presenc
thicker
nucleocapsid
paramyxovirus
envelop
anim
virus
nonseg
negativestrand
rna
genom
complementari
mrna
identifi
almost
exclus
nucleocapsid
structur
hpiv
genom
compris
approxim
nucleotid
encod
six
common
structur
protein
larg
l
nucleocapsid
protein
p
n
close
associ
viral
rna
haemagglutininneuraminidas
hn
fusion
f
membran
protein
tabl
templat
paramyxoviru
rna
synthesi
nake
rna
rather
helic
nucleocapsid
core
viru
compris
viral
rna
vrna
togeth
n
p
l
protein
n
protein
bind
vrna
creat
templat
l
rnadepend
rna
polymeras
p
protein
transcrib
replic
hpiv
genom
nucleocapsid
protein
n
protein
associ
precis
nucleotid
nt
consequ
associ
paramyxoviru
genom
effici
replic
number
nucleotid
genom
divis
describ
rule
six
human
parainfluenza
viru
type
enter
cell
directli
fuse
cell
membran
entri
viral
surfac
glycoprotein
hn
receptorbind
protein
f
cooper
mediat
fusion
upon
receptor
bind
first
step
toward
viral
replic
fusion
viru
host
cell
membran
hpiv
nucleocapsid
subsequ
expuls
cell
cytoplasm
transcript
occur
use
lp
rna
polymeras
complex
first
step
nencapsid
negativesens
rna
genom
transcrib
produc
low
level
viral
mrna
subsequ
genom
replic
complementari
nencapsid
antigenom
follow
gener
progeni
genom
next
secondari
transcript
progeni
genom
occur
gener
larg
burst
viral
mrna
cellular
ribosom
translat
mrna
viral
protein
negativesens
rna
produc
subsequ
encapsid
n
p
protein
may
export
new
virion
hpiv
effect
replic
lower
upper
airway
epitheli
cell
without
kill
cell
hpiv
infect
airway
epitheli
cell
induc
upregul
express
gener
sever
proinflammatori
tissu
remodellingrel
cytokin
pdgf
vegf
pattern
cytokin
releas
might
contribut
prolong
airway
inflamm
airway
structur
chang
typic
asthma
foetal
lung
fibroblast
infect
hpiv
releas
array
cytokin
includ
proinflammatori
cytokin
antiinflammatori
cytokin
cytokin
cytokin
granulopoiesisinduc
cytokin
granulocyt
colonystimul
factor
granulocytemacrophag
colonystimul
factor
neutrophil
recruitmentinduc
cytokin
interferoninduc
eosinophil
recruitmentinduc
cytokin
eotaxin
rant
recent
studi
report
infect
human
airway
epitheli
cell
rpmi
might
induc
express
releas
interferon
gamma
potenti
contribut
local
antivir
defenc
addit
although
rant
protein
concentr
mrna
express
significantli
increas
infect
measur
concentr
tslp
gmcsf
eotaxin
detect
virusinfect
cell
supernat
power
first
line
extracellular
defenc
paramyxovirus
within
respiratori
tract
complement
exist
rel
low
level
mucos
surfac
whose
concentr
dramat
increas
upon
cell
injuri
associ
infect
parainfluenza
virus
contain
glycoprotein
may
activ
complement
factor
via
altern
pathway
extent
activ
invers
correl
sialic
acid
concentr
either
viral
particl
infect
cell
reflect
presenc
hn
neuraminidas
activ
specif
host
defenc
hpiv
primarili
mediat
humor
immun
direct
two
surfac
glycoprotein
hn
f
preval
antibodi
parainfluenza
viru
type
increas
age
becom
twice
preval
among
older
adult
year
old
among
younger
individu
year
old
norway
parainfluenza
viru
antibodi
titr
preval
type
type
detect
accumul
percentag
adult
gener
popul
moreov
immunolog
respons
hpiv
infect
mediat
primarili
antibodi
belong
subclass
howev
infect
adult
addit
demonstr
increas
serum
level
igm
iga
infect
approxim
twothird
children
first
year
life
caus
symptomat
diseas
approxim
onethird
age
year
children
demonstr
serolog
evid
infect
immun
develop
later
immun
increas
rapidli
second
third
year
life
contrast
immun
develop
later
occur
among
schoolag
children
cytotox
tlymphocyt
respons
hpiv
infect
direct
determin
hn
p
np
protein
import
clearanc
lower
respiratori
tract
moreov
inhibit
cell
function
induct
larg
amount
reduc
cell
prolif
respons
protect
cell
virusmedi
apoptosi
mechan
suggest
potenti
explan
persist
hpiv
infect
human
paramyxovirus
develop
variou
strategi
overcom
host
innat
immun
respons
despit
genom
size
restrict
six
princip
gene
virus
produc
accessori
protein
isoform
v
c
within
p
gene
act
interferon
antagonist
protein
target
signal
molecul
ifn
system
includ
melanoma
differentiationassoci
factor
retinoid
acidinduc
gene
rig
ifn
regulatori
factor
signal
transduc
activ
transcript
divers
member
paramyxoviru
famili
negativestrand
rna
virus
effect
suppress
host
innat
immun
respons
v
protein
protein
mediat
interfer
interferon
regulatori
rna
helicas
avoid
cellular
antivir
respons
v
protein
bind
inhibit
ifn
induct
moreov
lu
et
al
show
within
member
rubulaviru
genu
v
protein
essenti
inhibit
dsrnamedi
signal
interact
kinas
inhibit
phosphoryl
intriguingli
paramyxoviru
studi
date
evad
ifninduc
antivir
respons
v
protein
degrad
stat
affect
local
phosphoryl
protein
stat
target
respirovirus
markedli
differ
paramyxovirus
reflect
express
anoth
accessori
protein
c
p
gene
protein
suffici
antagon
virus
sensit
neutral
complement
factor
parainfluenza
virus
also
delay
inhibit
complement
activ
previous
describ
viral
genom
small
none
viral
protein
exhibit
direct
anticompl
activ
therefor
parainfluenza
virus
deriv
benefit
normal
cellular
pathway
block
complement
activ
protect
potenti
cellular
damag
parainfluenza
virus
incorpor
membranebound
host
mediat
cleavag
inhibit
complex
format
virion
envelop
bud
therebi
delay
complementmedi
neutral
wherea
nasopharynx
oropharynx
primari
locat
initi
hpiv
replic
hpiv
also
associ
upper
lower
respiratori
tract
ill
includ
common
cold
laryngotracheobronch
ie
croup
tracheobronch
bronchiol
pneumonia
children
adult
although
infect
rather
mild
healthi
individu
may
lead
seriou
respiratori
diseas
children
immunocompromis
individu
follow
experiment
infect
adult
first
symptom
manifest
day
postinocul
last
day
averag
day
day
respect
despit
compat
common
cold
diagnosi
ill
rather
sever
manifest
nasal
discharg
frequent
becam
mucopurul
last
week
adult
patient
develop
mild
cough
without
sign
sever
lower
respiratori
tract
involv
typic
observ
children
infect
parainfluenza
virus
addit
patient
infect
strike
predomin
pharyng
observ
hpiv
serotyp
share
common
structur
replic
strategi
virus
target
differ
part
respiratori
tract
may
caus
differ
clinic
manifest
tabl
base
specif
serotyp
report
differ
kinet
replic
cytokin
releas
may
reflect
differ
serotypespecif
clinic
manifest
infect
howev
recent
larg
studi
china
base
analys
throat
swab
collect
approxim
children
adult
upper
lower
respiratori
tract
infect
challeng
dogma
hpivserotyp
specif
airway
symptom
author
report
clinic
spectrum
respiratori
symptom
associ
hpiv
infect
differ
regardless
four
hpiv
type
detect
biennial
fall
epidem
constitut
minimum
croup
case
usa
major
infect
occur
children
age
month
peak
incid
observ
second
third
year
life
young
infant
caus
lower
respiratori
ill
lri
howev
full
burden
viru
yet
determin
adult
elderli
popul
also
lead
lri
particularli
children
younger
year
although
viru
report
much
less
frequent
potenti
reflect
difficulti
isol
detect
unlik
hpiv
syndrom
nearli
half
infect
manifest
bronchiol
pneumonia
occur
within
first
year
life
moreov
receiv
much
attent
research
studi
compar
viru
subtyp
reflect
isol
detect
difficulti
howev
develop
molecular
techniqu
facilit
improv
character
epidemiolog
diseas
associ
frost
et
al
conduct
uniqu
largescal
studi
document
similar
clinic
present
infect
author
also
show
hpiv
caus
croup
human
host
percentag
hpiv
infect
result
persist
infect
remain
unclear
among
haematopoiet
cell
transplant
recipi
hpiv
appear
repres
frequent
infect
estim
cumul
incid
addit
hpiv
viru
asymptomat
infect
detect
hn
f
protein
involv
cell
membran
fusion
associ
hpiv
infect
paramyxovirusinfect
cell
decreas
level
neuramin
acid
residu
surfac
persist
infect
cell
fuse
decreas
level
cell
surfac
neuramin
acid
fuse
uninfect
cell
contain
neuramin
acid
studi
author
specul
persist
infect
achiev
high
moi
inoculum
viru
reflect
fact
high
level
neuraminidas
induc
rapid
destruct
cell
surfac
sialic
acid
prevent
viral
spread
celltocel
fusion
moreov
ahty
et
al
demonstr
phenomenon
also
depend
viru
serotyp
author
show
infect
high
moi
block
cell
fusion
case
infect
find
would
explain
infect
control
programm
focus
diseas
symptom
ineffect
piv
viral
infect
caus
paramyxovirida
famili
eg
rsv
implic
induct
transient
asthmat
symptom
children
also
persist
asthmat
phenotyp
later
life
patient
hospit
rsv
rhinoviru
bronchiol
first
year
life
increas
risk
asthma
year
age
compar
control
popul
infect
hpiv
childhood
postul
induc
similar
effect
viru
may
uniqu
featur
trigger
immun
reprogram
result
chronic
asthma
phenotyp
respiratori
viral
infect
consid
frequent
caus
asthma
copd
exacerb
rhinovirus
commonli
involv
howev
epidemiolog
experiment
data
strongli
suggest
role
parainfluenza
virus
exacerb
chronic
respiratori
disord
summari
find
present
tabl
hpiv
consid
import
caus
agent
virusinduc
asthma
exacerb
longitudin
studi
asthma
subject
nicholson
et
al
reveal
hpiv
infect
occur
asthma
exacerb
rhinovirus
coronavirus
rank
third
among
nonbacteri
caus
associ
asthma
symptom
children
year
old
bronchial
hyperreact
johnson
et
al
detect
hpiv
respiratori
episod
case
small
group
adult
asthmat
asthma
exacerb
case
infect
among
individu
infect
mild
coldinduc
asthma
exacerb
signific
releas
cysteinyl
leukotrien
induc
sputum
observ
frost
et
al
largescal
retrospect
analysi
specimen
collect
children
respiratori
symptom
reveal
sampl
posit
sampl
posit
hpiv
collect
children
asthma
howev
signific
differ
observ
preval
four
hpiv
serotyp
subject
anoth
studi
nasopharyng
sampl
collect
children
lower
respiratori
tract
infect
sampl
posit
parainfluenza
viru
detail
analysi
reveal
hpiv
present
bronchiti
patient
sampl
asthma
patient
sampl
pneumonia
patient
sampl
bronchiol
patient
sampl
lee
et
al
summar
histor
data
estim
agespecif
rate
acut
respiratori
ill
ari
lri
hospit
result
infect
among
us
children
year
age
author
show
agespecif
rate
might
vari
fivefold
differ
studi
conduct
differ
popul
use
differ
clinic
laboratori
definit
annual
medic
burden
children
younger
year
estim
million
case
medic
attend
ari
million
case
lri
case
hospit
marx
et
al
demonstr
respect
epidem
season
among
commonli
identifi
infect
adult
patient
hospit
lower
respiratori
tract
infect
account
episod
respect
azevedo
et
al
show
viral
identif
rate
hpiv
detect
frequenc
higher
asthmat
children
suggest
potenti
suscept
viral
infect
subgroup
zhu
et
al
suggest
viru
detect
chines
children
acut
respiratori
infect
includ
respiratori
virus
consid
rel
uncommon
particularli
sever
arirel
clinic
ill
manifest
studi
hpiv
detect
specimen
less
common
respiratori
syncyti
viru
adenoviru
human
rhinoviru
metapneumoviru
human
bocaviru
coronavirus
glezen
et
al
examin
patient
hospit
pneumonia
tracheobronch
bronchiol
croup
asthma
copd
exacerb
show
hpiv
rank
third
common
caus
seriou
acut
respiratori
condit
rsv
influenza
viru
viral
infect
also
associ
copd
exacerb
consid
respiratori
virus
frequent
detect
upper
lower
respiratori
tract
sampl
systemat
review
studi
patient
reveal
parainfluenza
viru
infect
associ
copd
exacerb
although
hpiv
fifth
frequent
infect
preval
diseas
higher
adenoviru
hmpv
bocavirus
recent
prospect
studi
copd
patient
viral
infect
detect
exacerb
although
rhinoviru
frequent
isol
viru
parainfluenza
fourth
preval
virus
account
copd
exacerb
thu
parainfluenza
virus
includ
among
potenti
trigger
copd
exacerb
tabl
epidemiolog
data
suggest
caus
role
hpiv
exacerb
chronic
airway
diseas
asthma
copd
support
experiment
data
anim
model
airway
inflamm
anim
model
allergeninduc
pulmonari
diseas
infect
result
inflammatori
cell
recruit
concomit
increas
airway
respons
histamin
follow
infect
allergeninduc
airway
obstruct
ovalbuminsensit
anim
shift
two
typic
transient
phase
singl
sustain
respons
last
h
interact
viral
allergyinduc
pulmonari
inflamm
may
alter
bronchial
smooth
muscl
respons
allergyinduc
pulmonari
obstruct
last
longer
resist
glucocorticoid
treatment
suggest
infect
asthmat
patient
similar
rhinoviru
infect
may
decreas
effect
glucocorticoid
treatment
parainfluenza
virus
major
caus
postinfecti
olfactori
dysfunct
comparison
monthli
frequenc
disord
incid
isol
variou
virus
suggest
parainfluenza
viru
type
rather
influenza
viru
respiratori
syncyti
viru
herp
viru
like
caus
agent
anoth
studi
patient
postvir
olfactori
disord
increas
serum
antibodi
titr
parainfluenza
viru
type
furthermor
parainfluenza
viru
detect
turbin
epitheli
cell
postvir
olfactori
dysfunct
patient
compar
control
patient
studi
suggest
potenti
role
hpiv
infect
pathogenesi
chronic
rhinosinus
frequent
associ
sever
form
asthma
includ
aspirinexacerb
respiratori
diseas
tabl
lower
respiratori
tract
infect
caus
differ
virus
includ
hpiv
lead
exacerb
chronic
respiratori
diseas
earli
antivir
treatment
could
potenti
prevent
exacerb
although
effect
antivir
treatment
hpiv
avail
clinic
practic
new
strategi
may
applic
hpiv
respiratori
infect
develop
direct
approach
base
interfer
viral
entri
remov
sialic
acid
receptor
use
bind
parainfluenza
hn
protein
therebi
prevent
first
step
infect
recombin
sialidas
protein
suggest
effect
inhibit
hpiv
infect
desialyl
antihpiv
activ
describ
hae
cotton
rat
infect
model
data
suggest
antihpiv
strategi
warrant
studi
assess
potenti
clinic
util
hpiv
infect
suggest
likelihood
develop
antivir
agent
hpiv
anoth
therapeut
concept
base
peptid
insert
cell
membran
may
enabl
use
fusioninhibitori
peptid
virus
fuse
cell
interior
porotto
et
al
report
ad
cholesterol
moieti
paramyxoviru
hrcderiv
peptid
significantli
increas
antivir
potenc
author
suggest
enhanc
activ
reflect
target
peptid
plasma
membran
fusion
occur
cholesteroltag
peptid
cell
surfac
creat
protect
antivir
shield
directli
target
f
protein
site
action
expand
potenti
util
inhibitori
peptid
paramyxovirus
antivir
potenc
shown
increas
cholesterol
tag
combin
dimer
hrderiv
sequenc
observ
human
parainfluenza
viru
nipah
viru
despit
multipl
attempt
past
decad
develop
clinic
test
liveattenu
vaccin
current
licenc
vaccin
avail
prevent
treatment
human
parainfluenza
infect
classic
jennerian
approach
relat
virus
heterolog
speci
examin
potenti
vaccin
candid
therebi
bovin
describ
promis
candid
viru
gener
mark
respons
seroneg
children
adult
despit
produc
signific
immun
respons
seroposit
subject
live
attenu
vaccin
evalu
phase
clinic
trial
wherein
administ
intranas
infant
month
age
trial
demonstr
safe
well
toler
infant
moreov
immun
elicit
humor
antibodi
respons
crossreact
vaccin
use
phase
trial
prepar
use
foetal
rhesu
monkey
cell
attempt
necessari
identifi
suitabl
cell
substrat
commerci
product
given
routin
vaccin
manufactur
use
cell
feasibl
promis
result
obtain
antigen
genet
stabl
attenu
strain
deriv
use
classic
attenu
approach
success
passag
lower
temperatur
cold
adapt
appear
even
immunogen
recent
cdnaderiv
recombin
vaccin
develop
contain
known
attenu
mutat
present
biolog
deriv
viru
genet
modif
enabl
use
viru
short
wellcharacter
passag
histori
vaccin
evalu
phase
trial
children
month
old
receiv
two
dose
vaccin
week
apart
first
dose
safe
infect
similar
biolog
deriv
viru
howev
second
dose
fail
boost
serum
antibodi
respons
englund
et
al
confirm
safeti
accept
toler
good
rate
infect
antibodi
respons
follow
singl
dose
vaccin
moreov
author
demonstr
two
dose
administ
month
apart
infect
children
year
age
infect
singl
dose
vaccin
senchi
et
al
examin
effect
oligomannoseco
liposom
oml
antigendeliveri
system
combin
synthet
doublestrand
rna
analogu
induct
mucos
systemat
immun
author
show
intranas
administr
haemagglutininneuraminidas
protein
encapsul
oml
synthet
doublestrand
rna
adjuv
polyriboinosinicpolyribocytidyl
acid
poli
c
gener
signific
viralspecif
system
mucos
immun
respons
evidenc
promin
induct
serum
igg
nasal
wash
iga
respect
recent
liveattenu
vaccin
design
evalu
phase
clinic
trial
adult
children
children
effect
vaccin
could
prevent
substanti
amount
respiratori
tract
ill
young
children
overattenu
children
thu
despit
decad
research
sever
vaccin
test
experiment
condit
vaccin
current
licenc
prevent
hpiv
infect
consid
biolog
viru
wide
rang
symptom
observ
children
adult
hpiv
infect
role
parainfluenza
virus
respiratori
tract
infect
must
neglect
moreov
hpiv
infect
import
caus
viral
exacerb
chronic
airway
diseas
asthma
copd
potenti
caus
role
hpiv
chronic
rhinosinus
also
suggest
studi
biolog
viru
hostviru
interact
requir
allow
develop
specif
therapi
may
counteract
exacerb
chronic
respiratori
diseas
